Alfuzosin

Alfuzosin is an alpha-1 adrenergic receptor antagonist, commonly called an alpha blocker, used chiefly to treat the lower urinary tract symptoms of benign prostatic hyperplasia, the non-cancerous prostate enlargement common in older men ^[1]. Alpha blockers are considered a first-line medical option for these symptoms because they act quickly to ease difficulty with urination, and unlike some other therapies they relieve symptoms without reducing prostate size ^[1]. Alfuzosin is often described as relatively uroselective, meaning it tends to act on the urinary tract with a comparatively modest effect on blood pressure ^[3].

In practice, alfuzosin improves urinary flow and reduces the frequency, urgency, and incomplete emptying that trouble men with an enlarged prostate, and studies report improvements in both symptom scores and quality of life ^[2]. Comparative trials have found its effectiveness broadly similar to that of another widely used alpha blocker, tamsulosin, with a comparable tolerability profile ^[3]. Beyond prostate symptoms, alpha blockers including alfuzosin have been used off-label to help small stones pass through the ureter, and analyses of such use report higher stone-clearance rates than conservative treatment alone ^[4].

Alfuzosin was first developed in the early 1980s, initially explored as a blood pressure medicine and later established for prostate symptoms; a once-daily extended-release tablet is the usual modern formulation ^[1]. It is a prescription medicine marketed under names such as Uroxatral and Xatral and is widely available as a generic ^[1]. Because it can lower blood pressure, particularly on standing, it is used with some caution, though its uroselective profile limits this effect for many patients ^[2][3].

Alfuzosin is prescription only. The most common side effects are dizziness, headache, fatigue and nasal congestion; because it relaxes vascular tone it can cause a drop in blood pressure on standing, especially with the first few doses. It carries a risk of intraoperative floppy iris syndrome, so anyone planning cataract surgery should tell their eye surgeon. It is metabolized by CYP3A4, so strong inhibitors such as ketoconazole, itraconazole or ritonavir can raise its levels and should be avoided; combining it with other blood pressure medicines or PDE5 inhibitors can add to the hypotensive effect. It is not recommended in moderate to severe liver impairment.

Alfuzosin is cleared almost entirely by CYP3A4, and that is the interaction that matters. Strong inhibitors including ketoconazole, itraconazole, ritonavir and clarithromycin raise its exposure several-fold, and co-administration is contraindicated because the consequence is marked hypotension, dizziness and syncope. Moderate inhibitors such as diltiazem raise exposure less but in the same direction.

The pharmacodynamic interactions follow from alpha-1 blockade. PDE5 inhibitors, nitrates, other antihypertensives and other alpha-blockers add to the fall in blood pressure, and the first-dose orthostatic response is where most syncope happens.

Alfuzosin prolongs the QT interval modestly, so exposure raised by a CYP3A4 inhibitor alongside another QT-prolonging drug is the shape of the worst case. It also predisposes to intraoperative floppy iris syndrome during cataract surgery, which is why surgeons ask about it well before the operation.

Checking a whole stack? Run it through interactions + stacks.

Alfuzosin is a quinazoline-derived alpha-1 adrenergic antagonist developed by the French pharmaceutical company Synthelabo and introduced in Europe in the late 1980s under the name Xatral. It was designed as a functionally uroselective alpha-blocker, concentrating in prostatic tissue relative to plasma, with the goal of easing bladder-outlet obstruction while limiting the blood-pressure effects common to earlier agents. A convenient once-daily extended-release 10 mg formulation, built around a three-layer matrix that releases the drug over roughly a full day, later became the standard, and the United States Food and Drug Administration approved it as Uroxatral in 2003. It remains a widely used first-line medical therapy for the urinary symptoms of benign prostatic hyperplasia.

Alfuzosin is well regarded among clinicians for delivering reliable symptom relief in benign prostatic hyperplasia while causing comparatively few sexual side effects, a distinction from some other alpha-blockers such as tamsulosin. Its favorable tolerability in men who also take antihypertensive medication or who have cardiovascular disease has helped sustain its popularity over decades of use. Systematic reviews continue to describe it as effective and safe, whether used on its own or combined with agents such as 5-alpha-reductase inhibitors, antimuscarinics, or PDE5 inhibitors. Like all alpha-blockers it can cause dizziness and, in some men undergoing cataract surgery, a phenomenon known as intraoperative floppy iris syndrome, so its benefits are best weighed individually.